Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BIIB144 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| BIIB144 Cohort 1 | EXPERIMENTAL | Participants will receive Dose A of BIIB144 or a matching placebo via intravenous (IV) infusion on Day 1. |
| BIIB144 Cohort 2 | EXPERIMENTAL | Participants will receive Dose B of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 3 | EXPERIMENTAL | Participants will receive Dose C of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 4 | EXPERIMENTAL | Participants will receive Dose D of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 5 | EXPERIMENTAL | Participants will receive Dose E of BIIB144 or a matching placebo via IV infusion on Day 1. |
| BIIB144 Cohort 6 | EXPERIMENTAL | Participants will receive Dose F of BIIB144 or a matching placebo via IV infusion on Day 1. |
| Name | Type | Description |
|---|---|---|
| BIIB144 | DRUG | Administered IV |
| Placebo | DRUG | Administered IV |
Key Inclusion Criteria: * Have a body mass index (BMI) between 18 and 32 kilograms per square metre (kg/m\^2), inclusive, at Screening. * Must be in good health as determined by the Investigator, based on medical history and Screening evaluations. Key Exclusion Criteria: * History of any clinical...
BIIB144 is an investigational small molecule being studied in healthy volunteers. It is currently in a Phase 1 clinical trial to evaluate the safety of a single dose and how it is processed in the body of healthy adult participants aged 18 to 55 years, compared to a placebo.
BIIB144 is being developed by Biogen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol BIIB. The company is conducting a Phase 1 clinical trial of BIIB144 in healthy volunteers in the United States.
BIIB144 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 study is recruiting participants to assess the safety and pharmacokinetics of a single dose of BIIB144 compared to placebo.
BIIB144 is being studied in one active Phase 1 clinical trial with the identifier NCT07662148. This randomized, double-blind, placebo-controlled study is enrolling 48 healthy adult participants aged 18 to 55 years in the United States to evaluate the safety and how the drug is processed in the body.
Yes, BIIB144 is a small molecule drug. It is being developed by Biogen Inc. and is currently in a Phase 1 clinical trial in healthy volunteers to assess its safety and pharmacokinetics following a single dose.